|Videos|December 21, 2022

State of The Art in Multiple Myeloma: Year in Review 2022

A video preview for an upcoming program reviewing clinical trial data and updates in the multiple myeloma treatment landscape over the last year.

Episodes in this series

EP. 1 State of The Art in Multiple Myeloma: Year in Review 2022

EP. 1 State of The Art in Multiple Myeloma: Year in Review 2022

Experts on MM

EP. 2 Induction Regimen Options in Transplant-Eligible NDMM

Experts on MM

EP. 3 DETERMINATION, GRIFFIN, and MASTER Studies

Experts on MM

EP. 4 Role of Transplant and Induction Therapies in NDMM

Experts on MM

EP. 5 Induction Therapy in Transplant-Ineligible NDMM

Experts on MM

EP. 6 Clinical Trials in Transplant-Ineligible NDMM

Experts on MM

EP. 7 Review of Patient Subgroups in Transplant-Ineligible NDMM

Experts on MM

EP. 8 Final Thoughts on Transplant-Ineligible Patients with MM

Expert on MM

EP. 9 Treatment Approaches for Patients with Relapsed-Refractory MM

Experts on MM

EP. 10 Treatment Selection of Bispecifics in Relapsed-Refractory MM

Experts on MM

EP. 11 Rationale for Bispecific-Based Combinations in MM

Experts on MM

EP. 12 The Role of Belantamab Mafodotin and Its Impact on Future Treatment Options

Expert on MM

EP. 13 Management of Bispecific Toxicities and Final Thoughts on Treatments in MM

Experts in the multiple myeloma space review available therapies such as CAR T-cell therapy, bispecifics, and B-cell maturation antigen–targeted agents for patients with multiple myeloma.

EP. 14 Evaluating Treatment Options by Patient Type in Multiple Myeloma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Rheumatoid arthritis RA in an autoimmune disease faultry activated b cells emitting antibodies which attack the joints causes inflammation front view 3d illustration. with copy space image | Image Credit © vxnaghiyev - stock.adobe.com

September 23rd, 2026

Optimizing Cilta-Cel Sequencing and Community Coordination in Multiple Myeloma

Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.

Trending on CancerNetwork

Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer

What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?

SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery

Tile-Based Radiation Improves Surgical Bed Recurrence in Brain Metastases

CARTITUDE-2 Cohort A Follow-Up Data and Preparing Patients for CAR TCell Therapy